468
Participants
Start Date
May 31, 2012
Primary Completion Date
September 30, 2014
Study Completion Date
July 31, 2015
botulinum toxin Type A
Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
Normal Saline
Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
Downey
Daytona Beach
Montreal
Prague
Wiesbaden
Würzburg
Budapest
Krakow
Krasnoyarsk
Gyeonggi-do
Stoke-on-Trent
Fazakerley
Lead Sponsor
Allergan
INDUSTRY